YM155 (Sepantronium Bromide)

Catalog No.S1130

For research use only.

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.

YM155 (Sepantronium Bromide) Chemical Structure

CAS No. 781661-94-7

Selleck's YM155 (Sepantronium Bromide) has been cited by 151 publications

Purity & Quality Control

Choose Selective Survivin Inhibitors

Other Survivin Products

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 M1v6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUe3NkBp M{nuW2ROW09? M4LhSGlEPTB;MD6wNFkhyrFiMD6wNFA6KM7:TR?= NILteoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
M-07e NVjwVpN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnneng4OiCq M3jzW2ROW09? NIHDTlVKSzVyPUCuNFQxKMLzIECuNFE{KM7:TR?= NXryfnRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
THP-1 NHq4T|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVG3NkBp NFm5UZhFVVOR MYLJR|UxRTBwMEWxJOKyKDBwMEGzJO69VQ>? NVvGRmtZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
CMK MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHIN3Z[PzJiaB?= NF6wWmVFVVOR NIfufo5KSzVyPUCuNFU{KMLzIECuNFA6KM7:TR?= NEW3bWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
MV4-11 M3jMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2GzUlczKGh? NE\PPZFFVVOR NVG4S2RrUUN3ME2wMlA2PSEEsTCwMlAzQCEQvF2= M1[xeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
AML-193 NFzyXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUC3NkBp NYXNOZBRTE2VTx?= NYrTWHhEUUN3ME2wMlQ3OiEEsTCwMlA3OCEQvF2= M2T1TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
HL-60 NF3WUWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PrZVczKGh? MXnEUXNQ MWrJR|UxRTBwMECxJOKyKDBwMECwNkDPxE1? MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
ML-2 M1nPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3ycoFDPzJiaB?= MVnEUXNQ NYezZVhxUUN3ME2wMlAxQSEEsTCwMlAxOiEQvF2= MoWyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUm3N|EoRjJ3NkW5O|MyRC:jPh?=
OCI/AML3 NVPRd|NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofHO|IhcA>? Ml\rSG1UVw>? M1K5RmlEPTB;MD6wNVEhyrFiMD6wNFIh|ryP MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
HEL NGfWWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVO3NkBp NXXZWYU5TE2VTx?= NF\6UGtKSzVyPUCuOVU6KMLzIECuNFM5KM7:TR?= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
ME-1 MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTFXodsPzJiaB?= M{TyemROW09? NVHvc45bUUN3ME2wMlY5PCEEsTCwMlE4QSEQvF2= M3\OW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
THP-1 MULBdI9xfG:|aYOgRZN{[Xl? M2W0cVHDqM7:TR?= MnvOO|IhcA>? MnH1SG1UVw>? MnLibY5lfWOnczDhdI9xfG:|aYO= NVLDO5JURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
M-07e MnLxSpVv[3Srb36gRZN{[Xl? MUSw5qCUOcLizszN NXvhOok6PzJiaB?= NHPXeYxFVVOR NUiwTGRNcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
THP-1 M{Lw[mZ2dmO2aX;uJGF{e2G7 MkC0NQKBmzIEoN88US=> MljmO|IhcA>? NIjUcWNFVVOR NH3xUmFqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu M{jaeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
CMK NXPGbI0{TnWwY4Tpc44hSXO|YYm= NGXHSHMx6oDVMdMg{txO MorhO|IhcA>? NF7sT5pFVVOR NETqc2JqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu NY[zU5B6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
AML-193 MYLGeY5kfGmxbjDBd5NigQ>? NEntNWEx6oDVMdMg{txO Mmr5O|IhcA>? MlXiSG1UVw>? NInmR|JqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
Kasumi-1 MlPYSpVv[3Srb36gRZN{[Xl? NWHTPZJoOOLCk{JCpO69VQ>? NIjwV404OiCq NH;lV5pFVVOR NVjNXmVqcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> M1\COFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
MV4-11 M1[yRWZ2dmO2aX;uJGF{e2G7 NF:4fpYx6oDVMdMg{txO M3\wTFczKGh? Mnv4SG1UVw>? NGPiOZBqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
MUG-Chor  MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rEeVAuPSEQvF2= NE\PW5MzPC92ODDo NWK1[HlKUUN3ME23MlA26oDLbl2g[o9zKDR6aB?= NVHBTGEzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OFAyQDVpPkK1OlQxOTh3PD;hQi=>
U-CH1  NVXHUHp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7yNE02KM7:TR?= NFjGUIozPC92ODDo MVvJR|UxRTlwMERihKlvVSCob4KgOFhp NV\P[oloRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OFAyQDVpPkK1OlQxOTh3PD;hQi=>
KATOIII M1jFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPaNVAwOjBibl2= MnjvOFghcA>? M1vodYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{XheFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkO1NFU2Lz5{NU[zOVA2PTxxYU6=
AGS  M37oWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWxNE8zOCCwTR?= MWG0PEBp NYfTdmpCcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MoTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4M{WwOVUoRjJ3NkO1NFU2RC:jPh?=
SACC-83 NWC1O3dQTnWwY4Tpc44hSXO|YYm= NYrlb2dCPSCwTR?= MnHsOFghcA>? MX3k[YNz\WG|ZYOgcpVkdGWjcjDlfJBz\XO|aX;uJI9nKEiLRj2x{tE> M4TwXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEi1OlM2Lz5{NUS4OVY{PTxxYU6=
INA-6 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXuN3ExNTVyMDDuUS=> MkT2OFghcA>? NIjBfXFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIS1SWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
U-266 M3\VdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWewMVUxOCCwTR?= NGeyOo01QCCq NXnVN3k2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O|g9N2F-
MOLP-8 M2nXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DK[|AuPTByIH7N M33ZcVQ5KGh? NY\Od2x6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVTtW4F3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
HG-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:wMVUxOCCwTR?= MUm0PEBp M3nuSIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFfCVok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
NCI-H929 MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnz5NE02ODBibl2= NVHPfGh[PDhiaB?= MUHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NF;0V2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
OPM-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3G1dVAuPTByIH7N NVrQZ3ExPDhiaB?= MUTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mm\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OU[5O|goRjJ3Mkm2PVc5RC:jPh?=
L-363 M3fQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DBUlAuPTByIH7N MoniOFghcA>? M2LpOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYK2dnQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
MOLP-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPkN4MxNTVyMDDuUS=> NUXXR41tPDhiaB?= MnvjbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4LrVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm2PVc5Lz5{NUK5Olk4QDxxYU6=
KMS-12-BM NHzUfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUWwMVUxOCCwTR?= MkizOFghcA>? NXfrNXRYcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUHnR4pNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
SK-MM-2 Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTkRmgxNTVyMDDuUS=> NUjIc29CPDhiaB?= M4TacYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NX[xO5FVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
U-266 MkH0RZBweHSxc3nzJGF{e2G7 MlrTNE02OCCwTR?= NGXZU3czPCCq NEHHNlJqdmS3Y3XzJIFxd3C2b4Ppdy=> NEGxb3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
INA-6  NIjv[ZNCeG:ydH;zbZMhSXO|YYm= NGrMOlQxNTVyIH7N M1vEN|I1KGh? M1i2SIlv\HWlZYOgZZBweHSxc3nz MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O|g9N2F-
MCF7 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvwO|IhcA>? NF3WZ5hKSzVyPUGzJOKyKDZibl2= M{PkPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKwNlI2Lz5{NUKyNFIzPTxxYU6=
MCF7-TamR6 M3i2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUe3NkBp NWT2[GpIUUN3ME24JOKyKDZibl2= M4DxSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKwNlI2Lz5{NUKyNFIzPTxxYU6=
MCF7-TamR7 NFr5NHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXmc3Q4OiCq NEnaZoZKSzVyPUigxtEhOyCwTR?= NIjoN4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNFIzPSd-MkWyNlAzOjV:L3G+
MCF7-TamR8 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnqzO|IhcA>? M1\nOWlEPTB;MUWgxtEhPiCwTR?= M3TiVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKwNlI2Lz5{NUKyNFIzPTxxYU6=
MCF7-TamC3 M{D3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLSd4l3PzJiaB?= NWf6N|ltUUN3ME22JOKyKDNibl2= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{MEKyOUc,OjV{MkCyNlU9N2F-
MCF7-TamC6 NGrhc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWK3NkBp Ml60TWM2OD14INMxJFAvOSCwTR?= NFLMW2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNFIzPSd-MkWyNlAzOjV:L3G+
MDA-MB-231 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYK3NkBp MYTJR|UxRTViwsGgNUBvVQ>? Mk[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MkCyNlUoRjJ3MkKwNlI2RC:jPh?=
SK-BR-3 M3rsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHVO|IhcA>? NIrNUmtKSzVyPUegxtEhOC5|IH7N NUD0TlJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNlAzOjVpPkK1NlIxOjJ3PD;hQi=>
Eca109 NFvzNXJHfW6ldHnvckBCe3OjeR?= MUGxMVUxKG6P Mmr0OFghcA>? NEDVfopFVVOR MV7zeZBxemW|c3XzJJN2en[rdnnuJIV5eHKnc4Ppc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MkX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzM{mzPVUoRjJ3MUO5N|k2RC:jPh?=
TE13 NGTae5FHfW6ldHnvckBCe3OjeR?= NUK2d3dNOS13MDDuUS=> M1rjSlQ5KGh? M{i0dWROW09? MYPzeZBxemW|c3XzJJN2en[rdnnuJIV5eHKnc4Ppc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NEjkV2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGzPVM6PSd-MkWxN|k{QTV:L3G+
Eca109 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrMSYRWOC1zMECgcm0> M2\TNlI1NzR6IHi= NHfjU2pFVVOR NX7iVG17\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NEX6clI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGzPVM6PSd-MkWxN|k{QTV:L3G+
TE13 M3LhRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3mzfVAuOTByIH7N MWKyOE81QCCq NHX1VHNFVVOR M4HYbIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1zkeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUO5N|k2Lz5{NUGzPVM6PTxxYU6=
MT-3 M1q4[GtqdmG|ZTDBd5NigQ>? Mn\YO|IhcA>? MmC5SG1UVw>? NV;JbXl7UUN3ME2yMlg3KMLzIECuOVQhdk1iZn;yJGRTPCCneIDy[ZN{cW:w NF73OIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2OlU5PSd-MkS4OlY2QDV:L3G+
MDA-MB-468 MoezT4lv[XOnIFHzd4F6 MV63NkBp MoPKSG1UVw>? NIHIeIpKSzVyPUCuNVEhyrFiMD6wNUBvVSCob4KgSHI1KGW6cILld5Nqd25? Ml7yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6Nk[1PFUoRjJ2OE[2OVg2RC:jPh?=
SUM-159 MVvLbY5ie2ViQYPzZZk> NWjQVopsPzJiaB?= NEPzOpVFVVOR MlHnTWM2OD1zLkeyJOKyKDBwM{Ogcm0h\m:{IFTSOEBmgHC{ZYPzbY9v M{XVb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OE[2OVg2Lz5{NEi2OlU5PTxxYU6=
MT-3 M1jRRmtqdmG|ZTDBd5NigQ>? NIHRdHo4OiCq NXG5UWJCTE2VTx?= NH7nZW1KSzVyPUW0MlEyKMLzIESuN|Ihdk1iZn;yJGRTPSCneIDy[ZN{cW:w M{jR[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OE[2OVg2Lz5{NEi2OlU5PTxxYU6=
MDA-MB-468 Ml7ET4lv[XOnIFHzd4F6 MkmzO|IhcA>? MnfaSG1UVw>? NFrWSmRKSzVyPUCuNFchyrFiMD6wNkBvVSCob4KgSHI2KGW6cILld5Nqd25? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh4NkW4OUc,OjR6Nk[1PFU9N2F-
SUM-159 MlfXT4lv[XOnIFHzd4F6 M2fyeFczKGh? Ml3KSG1UVw>? NGqyUYtKSzVyPU[5MlQhyrFiND6yN{BvVSCob4KgSHI2KGW6cILld5Nqd25? NGPpXIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2OlU5PSd-MkS4OlY2QDV:L3G+
MT-3 + NAC M{\QUWtqdmG|ZTDBd5NigQ>? NF7LTms4OiCq NWT1SG04TE2VTx?= M2XkeWlEPTB;NU[uNkDDuSB{LkC3JI5OKG[xcjDEVlUh\XiycnXzd4lwdg>? NXWzVGhiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OlY2QDVpPkK0PFY3PTh3PD;hQi=>
MT-3 + SB203580 MULLbY5ie2ViQYPzZZk> NWnHUGVwPzJiaB?= NIPUdnFFVVOR NX34eZZpUUN3ME2zPE41OSEEsTC1MlAzKG6PIH\vdkBFWjViZYjwdoV{e2mxbh?= M{HWc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OE[2OVg2Lz5{NEi2OlU5PTxxYU6=
DB NYfXeohGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr5NVAhdk1? NGPJNJMzPCCq Ml\oSG1UVw>? NYXwW4JscW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR6NkW5OUc,OjR2OE[1PVU9N2F-
SU-DHL-8 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfNOIlROTBibl2= NYPFS3c1OjRiaB?= M1vBc2ROW09? NWXDNmh{cW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR6NkW5OUc,OjR2OE[1PVU9N2F-
WSU-DLCL2 M3W1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLVNVAhdk1? MWKyOEBp NIjHVlVFVVOR M1rwfolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvci=> NGjpVW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES4OlU6PSd-MkS0PFY2QTV:L3G+
ACC-2 M2frS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELaXo4xNTFyMDDuUS=> Mn7VNlQhcA>? MYHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mnv0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|N{C5PVUoRjJ2M{ewPVk2RC:jPh?=
ACC-2 NXTuNmF6SXCxcITvd4l{KEG|c3H5 NE\HbXQxNTJyIH7N NGrMWlUzPCCq MkS4bY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NH;HRpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO3NFk6PSd-MkSzO|A6QTV:L3G+
ACC-2 NVy2T2hsTnWwY4Tpc44hSXO|YYm= NFLOWlMxNTJyIH7N NHfOZpIzPCCq MULpcoNz\WG|ZYOgeIhmKGOxbo\ldpNqd25ib3[gUGM{USC2bzDMR|NKUQ>? MmL6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|N{C5PVUoRjJ2M{ewPVk2RC:jPh?=
BFTC905 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLMUldxOC1zMECwJI5O MV[0PEBpyqB? MYrEUXNQ MljXTWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVu5[JlMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVc3PDRpPkK0Nlk4PjR2PD;hQi=>
T24 NEP3eGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7zNE0yODByIH7N Mnq2OFghcMLi NYjIWpNLTE2VTx?= NUizWIJ4UUN3ME2yNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mo\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUe2OFQoRjJ2Mkm3OlQ1RC:jPh?=
TSGH8301  NIK2U45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHtNE0yODByIH7N NFzTOms1QCCqwrC= NV3peVJTTE2VTx?= M4HERmlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{LtT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3OlQ1Lz5{NEK5O|Y1PDxxYU6=
BFTC909 NWjOPI5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmmwNE0yODByIH7N NUnRV4ZTPDhiaNMg NWnBSlZFTE2VTx?= MoDXTWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7N{[0OEc,OjR{OUe2OFQ9N2F-
BFTC905 NIjVVIRCeG:ydH;zbZMhSXO|YYm= MYKyNEBvVQ>? NEnvSpM1QCCq MoPCSG1UVw>? MXPpcoR2[2W|IHHwc5B1d3Orcx?= NIKzflE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5O|Y1PCd-MkSyPVc3PDR:L3G+
BFTC905 Mk\jSpVv[3Srb36gRZN{[Xl? MkLDNlAhdk1? NYXibWdmPDhiaB?= NEGwbmlFVVOR NGfQXnZl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVEN|Qj3JTS=> NF3scpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5O|Y1PCd-MkSyPVc3PDR:L3G+
A2780p NVPDSZdxTnWwY4Tpc44hSXO|YYm= MV6wMVExOCCwTR?= MV6yOEBp MlfKSG1UVw>? NE\FbVFqdmS3Y3XzJHN2en[rdnnuJIRwf26{ZXf1cIF1cW:wwrC= MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ4Mki3OUc,OjR{NkK4O|U9N2F-
A2780cis NF7UeVFHfW6ldHnvckBCe3OjeR?= MV6wMVExOCCwTR?= MnToNlQhcA>? Mnq1SG1UVw>? NUm1S2MxcW6mdXPld{BUfXK4aY\pckBld3ewcnXneYxifGmxbtMg MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ4Mki3OUc,OjR{NkK4O|U9N2F-
A2780p Moj3RZBweHSxc3nzJGF{e2G7 MW[1MVExOCCwTR?= Mne1NlQwPDhiaB?= MkD4SG1UVw>? MmDabY5kemWjc3XzJIFxd3C2b4Ppd{BqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ4Mki3OUc,OjR{NkK4O|U9N2F-
A2780cis NF7SS3VCeG:ydH;zbZMhSXO|YYm= NWfINlU2PS1zMECgcm0> MX:yOE81QCCq Mo\uSG1UVw>? MnnVbY5kemWjc3XzJIFxd3C2b4Ppd{BqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NHrmV5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK2Nlg4PSd-MkSyOlI5PzV:L3G+
SH-SY5Y MYfBdI9xfG:|aYOgRZN{[Xl? NGrtOXEyNzFyL{GwNEDDvU1? NX7Bbop5PzJiaB?= MljsSG1UVw>? M2fwWIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mn73QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NUS1OlAoRjJ2MkW0OVYxRC:jPh?=
HL-60 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mom5O|LDqGh? NWqyOWVVTE2VTx?= MVTJR|UxRTBwMzDuUS=> Mn3WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUi4OlIoRjJ|NkG4PFYzRC:jPh?=
U937  NGL5bmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYS3NuKhcA>? MojwSG1UVw>? NWrOfIQ5UUN3ME2wMlghdk1? Mn\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUi4OlIoRjJ|NkG4PFYzRC:jPh?=
HL-60  M1PFRWZ2dmO2aX;uJGF{e2G7 MmHvNeKh|ryP M1j1PVYwOTJxMkSgbC=> M3e2NGROW09? M{W0bIlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJN2en[rdnnu NYSwdJd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVg5PjJpPkKzOlE5QDZ{PD;hQi=>
U937  NVXFdXR4TnWwY4Tpc44hSXO|YYm= MVGxxsDPxE1? MnTMOk8yOi9{NDDo NHP6[lFFVVOR M1TUSYlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJN2en[rdnnu NITCeGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xPFg3Oid-MkO2NVg5PjJ:L3G+
HL-60 NYKyOGIzSXCxcITvd4l{KEG|c3H5 NX\KOIxjOC5zL{Gg{txO MmLrPEBp NXTYSGExTE2VTx?= MV;pcoR2[2W|IHHwc5B1d3Orcx?= NHjwN5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xPFg3Oid-MkO2NVg5PjJ:L3G+
Sk-NEP-1  M2nPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq0PI01OS1zMECwNEBvVQ>? M1T0[FI1KGh? M{HiOWROW09? M4fBOWlEPTB;MUCwJI5O NYPxUpBiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOlc3QTlpPkKzNlY4Pjl7PD;hQi=>
SK-NEP-1  MWXBdI9xfG:|aYOgRZN{[Xl? MV21NE8yODBibl2= M4fVXFEzNzJ2IHi= NHfWdmhFVVOR NXXCUFlRcW6mdXPld{BieG:ydH;zbZM> NF\mcpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K2O|Y6QSd-MkOyOlc3QTl:L3G+
TC-32 NVrybpJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLxXmZNOC5zLUGwNFAhdk1? M{LlcGVEPTB;Mz6wJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHjKOI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm2NVc3Oyd-MkK5OlE4PjN:L3G+
TC-71 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfxPI5WOC5zLUGwNFAhdk1? MYHFR|UxRTVwNzDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIfoSVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm2NVc3Oyd-MkK5OlE4PjN:L3G+
SK-ES-1 NF3mZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLpNE4yNTFyMECgcm0> MnLQSWM2OD1{Lkigcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWr2dnFyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5OlE4PjNpPkKyPVYyPzZ|PD;hQi=>
RD-ES M33MbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HkPFAvOS1zMECwJI5O M3TZcGVEPTB;Nj6yJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHXPN2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm2NVc3Oyd-MkK5OlE4PjN:L3G+
HEK293 M4X1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\yUFAvOS1zMECwJI5O M{\qXWVEPTB;MkOuNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnfMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NkG3OlMoRjJ{OU[xO|Y{RC:jPh?=
M059J NUTIRmx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDYNE02OCCwTR?= MY[0PEBp NXzIZlJocW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NED6SlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFEyOCd-MkK3O|AyOTB:L3G+
M059K NVu0VFBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCwMVUxKG6P MWe0PEBp M2jJXolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1W4RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ewNVExLz5{Mke3NFEyODxxYU6=
M059J M2X0ZWFxd3C2b4Ppd{BCe3OjeR?= Mn\zN|Ahdk1? NHvxbmgzPCCq M2fCO4lv\HWlZYOgZZBweHSxc3nz MnKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5N{CxNVAoRjJ{N{ewNVExRC:jPh?=
M059K M1XjdmFxd3C2b4Ppd{BCe3OjeR?= NFTOW5Q{OCCwTR?= NYrWUVJWOjRiaB?= NVOwTWYzcW6mdXPld{BieG:ydH;zbZM> NFHteY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFEyOCd-MkK3O|AyOTB:L3G+
PANC-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoS3NE4xOS1zMECwJI5O MorKOFghcA>? NWH6U5JSUUN3ME2zMlY6KG6P NUHHNGR2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3NlM5PzFpPkKyO|I{QDdzPD;hQi=>
MIAPaCa-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTiNE4xOS1zMECwJI5O NILveGY1QCCq MXXJR|UxRTJ7LkO2JI5O MoHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5MkO4O|EoRjJ{N{KzPFcyRC:jPh?=
BxPC-3 NH;udmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrORXhwOC5yMT2xNFAxKG6P MX60PEBp NEPGT|BKSzVyPUOwMlI3KG6P MlvLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5MkO4O|EoRjJ{N{KzPFcyRC:jPh?=
PANC-1 NVrjcnY3TnWwY4Tpc44hSXO|YYm= MWSwMVExODBibl2= NGDucJkzPCCq MWnpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGjJRXAh[W6mIIP1dpZqfmmwIHX4dJJme3Orb36= NHq1OXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkeyN|g4OSd-MkK3NlM5PzF:L3G+
MIAPaCa-2 NWH0RYZDTnWwY4Tpc44hSXO|YYm= NGSwd|cxNTFyMECgcm0> M3n2ZlI1KGh? NH7W[mdqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHhKSVBiYX7kJJN2en[rdnnuJIV5eHKnc4Ppc44> NGXvUnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkeyN|g4OSd-MkK3NlM5PzF:L3G+
BxPC-3 NYXCXZV{TnWwY4Tpc44hSXO|YYm= NWDUO2dSOC1zMECwJI5O M{LLOlI1KGh? NIXLWJZqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHhKSVBiYX7kJJN2en[rdnnuJIV5eHKnc4Ppc44> NXTDdGxCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3NlM5PzFpPkKyO|I{QDdzPD;hQi=>
RPMI-7951 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFflU4tIUTVyPUOuNkBvVQ>? NFi1UoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUezO|UxOid-MkG3N|c2ODJ:L3G+
SK-MEL-5 MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXrfmhIUTVyPUSuNkBvVQ>? NEPiUnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUezO|UxOid-MkG3N|c2ODJ:L3G+
A375 NH;6NpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPseIRIUTVyPU[uN{BvVQ>? NFzwXIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUezO|UxOid-MkG3N|c2ODJ:L3G+
SK-MEL-28 NXuxSI46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLhV|ZxT0l3ME23MlYhdk1? MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd|N{WwNkc,OjF5M{e1NFI9N2F-
SK-MEL-2 NFjaRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfFS2k2OD1zMTDuUS=> NXHzNXZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3N|c2ODJpPkKxO|M4PTB{PD;hQi=>
DB Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPFXVFwPDkEoHi= MVnHTVUxRTNwNTDuUS=> MmHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{M{e1NFgoRjJzMkO3OVA5RC:jPh?=
Pfeiffer MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7pS45sPDkEoHi= NHrIcmJIUTVyPUOuPUBvVQ>? M1nyOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkO3OVA5Lz5{MUKzO|UxQDxxYU6=
SU-DHL-5 MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnVZpNFPDkEoHi= MULHTVUxRTBwMkOgcm0> Mn7sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{M{e1NFgoRjJzMkO3OVA5RC:jPh?=
SU-DHL-8 NFzCe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHDOFjDqGh? M3HBc2dKPTB;MT60JI5O M1HudFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkO3OVA5Lz5{MUKzO|UxQDxxYU6=
WSU-DLCL-2 M3riUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTTcIdOPDkEoHi= MUDHTVUxRTFwNDDuUS=> NFvjT2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKzO|UxQCd-MkGyN|c2ODh:L3G+
A549 M3rHPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3\KNGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscJMtKEmFNUC9NE4xOTN2zszN Ml[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6MUSzO|QoRjJ6OEG0N|c1RC:jPh?=
DU145 MYfDfZRwfG:6aXPpeJkh[XO|YYm= MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BjgSCPVGSgZZN{[XluIFXDOVA:OC5yMUO4{txO NEfZWVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEe3OFQzPid-Mki3O|Q1OjZ:L3G+
PC3 NXzqXW5CS3m2b4TvfIlkcXS7IHHzd4F6 NH74dW1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[nliTWTUJIF{e2G7LDDFR|UxRTBwMEmy{txO NVrUS4w2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3O|Q1OjZpPkK4O|c1PDJ4PD;hQi=>
A549 NHvyWlVHfW6ldHnvckBie3OjeR?= NYHrWplyUW6qaXLpeIlwdiCxZjDQRWsyKGmwIHj1cYFvKEF3NEmgZ4VtdHNuIFnDOVA:OC53zszN M2nvSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEG0N|c1Lz5{OEixOFM4PDxxYU6=
Assay
Methods Test Index PMID
Western blot Survivin / XIAP / Caspase-7 / Caspase-9 / Caspase-3 / Cleaved Caspase-8 / PARP ; β-catenin / c-Myc / Cyclin D1 / CD44 ; p-STAT3 / STAT3 26771139 22723871
Immunofluorescence EGFR ; PARP-1 / PAR 22723871 26090615
Growth inhibition assay Cell viability 29636860
In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol (from reference)

Kinase Assay:

[1]

  • Promoter-luciferase reporter assay:

    A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5

Cell Research:

[1]

  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.

  • (Only for Reference)
Animal Research:

[1]

  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
  • (Only for Reference)

Solubility (25°C)

In vitro

Water 89 mg/mL
(200.77 mM)
DMSO 55 mg/mL
(124.07 mM)
Ethanol 6 mg/mL
(13.53 mM)

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.

30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01023386 Completed Drug: YM155 Cancer Astellas Pharma Inc November 2009 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor